This clinical trial is focused on studying the condition known as sarcoidosis, which is a disorder affecting the immune system. The study is evaluating the effects of stopping a treatment with a medication called infliximab, which is used to manage this condition. Infliximab is a type of medication known as a TNF-alpha antagonist, which helps reduce inflammation in the body. The purpose of the study is to compare two different strategies for maintaining remission, which means keeping the disease inactive, in patients who have already achieved remission after being treated with infliximab.
Participants in the study will be divided into groups to test these strategies. Some participants will continue with their current treatment, while others will stop taking infliximab. The study will monitor the participants over a period of time to see how many experience a major relapse, which is when the disease becomes active again. This will help researchers understand the best way to manage sarcoidosis after initial treatment with infliximab.
In addition to infliximab, the study also involves other medications such as methotrexate and azathioprine, which are taken in tablet form. Methotrexate is a chemical substance used to treat various immune system disorders, while azathioprine is another medication that helps suppress the immune system to prevent it from attacking the body. The study will last for up to 12 months, and participants will receive either the medication or a placebo during this time. The results will provide valuable information on how to best maintain remission in patients with sarcoidosis.
France 
